Dialysis Access Devices Articles & Analysis
16 news found
Quanta Dialysis Technologies Inc (“Quanta or “The Company”), a medical technology company committed to making kidney care more accessible with its SC+ hemodialysis system, announced today that CEO John E. Milad will leave the company effective July 15, 2022. The company has begun the search for a new CEO. Upon Milad’s departure and until the appointment of a new CEO, ...
QUANTA Dialysis Technologies Ltd (“QUANTA” or the “Company”), a medical technology company committed to making kidney care more accessible with its SC+ haemodialysis system, has released a new report that suggests people with kidney failure who wish to do home dialysis face unequal access across the UK. The Bridging the Gap report finds that failure to offer such treatment ...
Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company reducing the cost and complexity of dialysis, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for a new sterilization method of the cartridge utilized in its Tablo® Hemodialysis System, enabling full production in North America. The Tablo cartridge is a ...
Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2021. The Company also announced that Leslie Trigg has been appointed Chair of the Board of Directors in ...
Xeltis has initiated the clinical trial for aXess, the first-ever restorative synthetic haemodialysis access graft. Several patients with kidney failure or advanced kidney disease requiring dialysis have already been successfully implanted as part of a European first-in-human trial to date. The aXess grafts enable early puncturing, or initiation of the dialysis, shortly after implanting. ...
Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it has been named to Fast Company’s inaugural Next Big Things in Tech list, honoring the technology breakthroughs that promise to shape the future of their industries — from healthcare to ...
Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”, a medical technology company committed to making kidney care more accessible with its SC+ haemodialysis system), is proud to sponsor a new photography exhibition Survivors: Life Unfiltered, running from 26 October to 7 November 2021, at the OXO Gallery in London. This exhibition was created by award winning ...
Quanta Dialysis Technologies Ltd (“Quanta” of the “Company”, a medical technology company committed to making kidney care more accessible with its SC+ haemodialysis system, announced today the results of the UK Dialysis Patient Experience Survey, showing the wide variance in care experienced by UK dialysis patients, as well as challenges faced in assessing self-care and ...
On May 31, 2021, Mr. Dominic Barton, Canadian Ambassador to China, accompanied by Consul General Jeff David and trade commissioners from the Canadian Consulate General in Chongqing, visited SWS ...
PD is a method of dialysis allowing patients to administer their own dialysis treatments in their home. ...
The Ellipsys® Vascular Access System enables patients with kidney failure to start dialysis treatment sooner with fewer procedures, complications and interventions compared to surgery, according to several leading physicians who spoke at the recent meeting of the American Society of Diagnostic and Interventional Nephrology (ASDIN). Interventional radiologist Jeffrey Hull, M.D., was awarded ...
Solvay Ventures announces today its equity investment in Invizius, the University of Edinburgh spin-out developing potentially lifesaving products that reduce complications rates suffered by dialysis patients. Solvay Ventures invests alongside Mercia Asset Management, Downing Ventures, the University of Edinburgh’s Old College Capital fund and the Scottish Investment Bank. Invizius is ...
Pollet Medical Group, part of Pollet Group and mainly known for its water treatment activities under Pollet Water Group, integrates Hemotech & Hema.T Medical into their group. Both French companies are renomated experts in the market of hemodialysis and apheresis for dialysis centres and hospitals. Hemotech & Hema T. Medical deliver high quality medical devices intended to dialysis and ...
The clinical study will evaluate STARgraft as a vascular access graft for dialysis patients and will be conducted in collaboration with University of Washington Medicine. ...
It’s no secret that healthcare workers have tougher jobs than many other people. A recent poll sheds light on the difficult situation: healthcare employees are about as happy with their jobs as anyone else, yet feel less valued and struggle with work-life balance. For healthcare employers, job satisfaction impacts the bottom line most directly in the form of employee retention rates. Those ...
Titled, “Vascular Grafts for Needle Free Dialysis Access Devices,” the grant provides one-year funding to develop Healionics’ new STARgraft - a vascular graft based on STAR biomaterial that shows promise to reduce thrombosis and infection issues. “Our initial preclinical results showed that STARgraft is an exciting and ...